Victoza: who should not take it

Two separate questions get run together here: whether Victoza is suitable for you at all, and whether it interferes with something else you take. This page covers both, in that order — and neither can be settled from a web page. The point is knowing which questions to raise.

Who should not take it

Thyroid C-cell tumours

Victoza carries a boxed warning about thyroid C-cell tumours, based on rodent studies at clinically relevant exposures. Whether the same applies to humans has not been determined. The practical consequence is unambiguous: a personal or family history of medullary thyroid carcinoma, or of Multiple Endocrine Neoplasia syndrome type 2, rules this medicine out.

If thyroid cancer runs in your family, find out which kind. Most thyroid cancers are papillary or follicular and are not relevant here. Medullary is a different disease and it is the one that matters — and it is the exclusion people most often do not know applies to them.

Pregnancy and planned pregnancy

Weight loss during pregnancy offers no benefit to a developing fetus, and the weight-management products in this class are not for use in it. Because Victoza clears over about 3 days, stopping is not instantaneous — guidance calls for discontinuation well before a planned conception.

There is a further complication people are caught by: delayed gastric emptying can affect the absorption of oral contraceptives, and so can vomiting. That deserves its own conversation.

Previous pancreatitis

Pancreatitis appears in the warnings for every product in this class, although a causal relationship has not been established. A previous episode is not an automatic exclusion, but it changes the risk calculation and lowers the threshold for investigating abdominal pain later. The symptoms that matter are here.

Other cautions

Gallbladder disease. Rapid weight loss increases gallstone formation, and this class produces rapid weight loss.
Severe gastrointestinal disease or gastroparesis. These medicines work partly by slowing the stomach; in a stomach already emptying abnormally slowly, that is an obvious problem.
Diabetic retinopathy. Rapid improvement in glucose can transiently worsen existing disease — a known phenomenon with any rapid correction, not unique to this class.
Kidney impairment. The medicine is not directly nephrotoxic; the risk is dehydration from severe vomiting or diarrhoea, and existing impairment lowers the margin.
A history of an eating disorder. Not an exclusion, but a situation that needs supervision rather than avoidance.

What to say before you start

Five things, of which the first two are the ones most often left out — not because people conceal them, but because nobody asks in a way that surfaces them:

Any family history of thyroid cancer — and which type, if you know. Most kinds are irrelevant here; one is not.
Whether you are pregnant, might be, or are planning to be — including what contraception you use.
Any previous pancreatitis, gallbladder disease or gastrointestinal surgery.
Every medicine and supplement you take, including over-the-counter and herbal ones.
Any history of an eating disorder. Not an exclusion — a reason for the treatment to be supervised differently.

None of these is likely to produce a refusal. All of them are reasons for the conversation to happen before the first dose rather than after a problem, and all of them are easier to say once, at the start, than to raise later.

Medicines that need attention

Almost all of the interaction risk with Victoza comes from a single mechanism: a slower stomach changes the rate at which oral medicines are absorbed. For most medicines that changes nothing that matters. It matters where the margin between an effective and a harmful dose is narrow.

Insulin and sulfonylureas

The clearest and most important one, and it is not about absorption. Victoza lowers glucose; insulin and sulfonylureas lower glucose. Together, the risk of hypoglycaemia rises materially, and prescribers commonly reduce those doses when starting — and again during escalation. What a low feels like and what to do is here.

Narrow-margin medicines

Warfarin and other anticoagulants — control is measured rather than assumed, and more frequent monitoring during the first months is a reasonable precaution.
Thyroid hormone — absorption-sensitive, narrow margin, and usually taken on an empty stomach.
Digoxin, lithium, some anti-epileptics and immunosuppressants — none prohibited, all worth a specific conversation.

Not to be combined

Two GLP-1 products are not taken together — the mechanisms overlap and side effects compound without added benefit. The same applies to combining one with a DPP-4 inhibitor such as sitagliptin, which works by preventing the breakdown of your own GLP-1.

Surgery, endoscopy and sedation

The interaction people are least likely to think of and the one with the sharpest consequences. A stomach that empties slowly may still contain food after a standard fasting period, which matters for anaesthesia and for endoscopy.

Tell any surgeon, anaesthetist, dentist or endoscopist that you take Victoza — at booking, not on the day. Guidance commonly involves holding a dose beforehand, and the interval depends on the product. The detail is here.

What is not an interaction

Most antibiotics, painkillers and blood pressure medicines are unaffected in any way that matters.
Common supplements are generally fine, though very large doses of anything are worth mentioning.
Food is not an interaction for the injectable products in this class — they are taken with or without it.

The step that catches most of it

Give your pharmacist a complete list of what you take — prescription medicines, over-the-counter medicines, supplements and anything herbal — and ask them to check it against a new Victoza prescription. Pharmacists are better at this than anyone else in the system and are routinely under-used for it.

And keep the list current. The interaction that causes trouble is rarely the one considered at the start — it is the medicine prescribed six months later by someone who does not know about this one. The wider picture is here.

Where this fits

This page covers one product. Three things about GLP-1 treatment are the same whichever product you are on, and they explain most of what happens month to month:

The mechanism. Almost every side effect and every benefit traces back to the same three actions — insulin release, a slower stomach, and appetite signalling in the brain.
The arithmetic. Half-life explains the weekly schedule, the slow first month, the forgiving missed-dose window, and why stopping is gradual whether you intend it to be or not.
What you lose. Weight lost quickly, on low protein and without resistance training, includes a meaningful share of lean tissue. This is the least discussed part of the treatment and the one with the longest consequences.

Common questions

Can Victoza be taken with insulin?

Yes, and it commonly is. The combination raises hypoglycaemia risk and insulin doses are usually reduced at the start. Monitoring more often during the first fortnight is standard.

Does Victoza interact with metformin?

No interaction that matters, and the combination is routine. Metformin does not add hypoglycaemia risk the way insulin or a sulfonylurea does.

A note on sources. The figures on this page come from the manufacturer's approved labelling and from published pharmacokinetic data. Regional labels differ — sometimes materially — so where a number matters, the leaflet in your own box outranks anything written here. Our editorial standards set out how these pages are sourced and corrected.